TABLE OF CONTENTS
1 INTRODUCTION 92
1.1 OBJECTIVES OF THE STUDY 92
1.2 MARKET DEFINITION 92
1.3 OVERVIEW OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 92
1.4 CURRENCY AND PRICING 95
1.5 LIMITATIONS 95
1.6 MARKETS COVERED 95
2 MARKET SEGMENTATION 99
2.1 MARKETS COVERED 99
2.2 GEOGRAPHICAL SCOPE 100
2.3 YEARS CONSIDERED FOR THE STUDY 101
2.4 DBMR TRIPOD DATA VALIDATION MODEL 102
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 105
2.6 MULTIVARIATE MODELLING 106
2.7 MARKET END USER COVERAGE GRID 107
2.8 PRODUCT LIFELINE CURVE 108
2.9 DBMR MARKET POSITION GRID 109
2.10 VENDOR SHARE ANALYSIS 110
2.11 SECONDARY SOURCES 111
2.12 ASSUMPTIONS 111
3 EXECUTIVE SUMMARY 112
4 PREMIUM INSIGHTS 115
4.1 PESTEL ANALYSIS 118
4.2 PORTERS FIVE FORCES MODEL 119
5 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 120
6 EPIDEMIOLOGY 122
7 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 123
8 MARKET OVERVIEW 126
8.1 DRIVERS 128
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 128
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 128
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 129
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 129
8.2 RESTRAINTS 130
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 130
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 130
8.3 OPPORTUNITIES 131
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 131
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 132
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 132
8.4 CHALLENGES 133
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 133
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 133
9 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 134
9.1 OVERVIEW 135
9.2 IMAGING TEST 138
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 139
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 139
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 139
9.2.2.2 MR ANGIOGRAPHY (MRA) 140
9.2.3 ULTRASOUND 140
9.2.3.1 ABDOMINAL ULTRASOUND 140
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 140
9.2.4 CHOLANGIOPANCREATOGRAPHY 140
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 141
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 141
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 141
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 141
9.2.6 OTHERS 141
9.3 BIOPSY 142
9.3.1 CT-GUIDED NEEDLE BIOPSY 143
9.3.2 FINE NEEDLE ASPIRATION (FNA) 143
9.3.3 CORE NEEDLE BIOPSY 143
9.3.4 OTHERS 143
9.4 BLOOD TEST 143
9.4.1 LIVER FUNCTION TEST 144
9.4.2 TUMOR MARKER 144
9.4.2.1 CA 19-9 BIOMARKER TEST 145
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 145
9.4.2.3 CA 50 MARKER TEST 145
9.4.2.4 OTHERS 145
9.4.3 OTHERS 145
9.5 GENOMIC TEST 146
9.6 OTHERS 147
10 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 148
10.1 OVERVIEW 149
10.2 STAGE IV 152
10.3 STAGE III 152
10.4 STAGE II 153
10.4.1 STAGE IIA 154
10.4.2 STAGE IIB 154
10.5 STAGE I 154
10.5.1 STAGE IA 155
10.5.2 STAGE IB 155
10.6 STAGE 0 156
11 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 157
11.1 OVERVIEW 158
11.2 EXOCRINE TUMORS 161
11.2.1 INSTRUMENT-BASED PRODUCTS 162
11.2.2 PLATFORM-BASED PRODUCTS 162
11.2.3 KITS AND REAGENTS 162
11.2.4 OTHER CONSUMABLES 162
11.3 NEUROENDOCRINE TUMORS 162
11.3.1 INSTRUMENT-BASED PRODUCTS 163
11.3.2 PLATFORM-BASED PRODUCTS 163
11.3.3 KITS AND REAGENTS 164
11.3.4 OTHER CONSUMABLES 164
12 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 165
12.1 OVERVIEW 166
12.2 INSTRUMENT-BASED PRODUCTS 169
12.2.1 IMAGING 170
12.2.2 BIOPSY 170
12.3 PLATFORM-BASED PRODUCTS 170
12.3.1 NEXT-GENERATION SEQUENCING 171
12.3.2 MICROARRAYS 171
12.3.3 PCR 171
12.3.4 OTHERS 172
12.4 KITS AND REAGENTS 172
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 173
12.4.1.1 ELISA TEST KITS 173
12.4.1.2 CASETTE TEST KITS 173
12.4.1.3 OTHERS 173
12.4.2 CEA PANCREATIC CANCER TEST KITS 174
12.4.2.1 ELISA TEST KITS 174
12.4.2.2 CASETTE TEST KITS 174
12.4.2.3 OTHERS 174
12.5 OTHER CONSUMABLES 174
13 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 176
13.1 OVERVIEW 177
13.2 FLUORESCENT IN SITU HYBRIDIZATION 180
13.3 NEXT GENERATION SEQUENCING 181
13.4 FLUORIMMUNOASSAY 182
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 183
13.6 IMMUNOHISTOCHEMICAL 184
13.7 OTHERS 185
14 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 186
14.1 OVERVIEW 187
14.2 SCREENING 190
14.2.1 INSTRUMENT-BASED PRODUCTS 191
14.2.2 PLATFORM-BASED PRODUCTS 191
14.2.3 KITS AND REAGENTS 191
14.2.4 OTHER CONSUMABLES 191
14.3 DIAGNOSTIC AND PREDICTIVE 191
14.3.1 INSTRUMENT-BASED PRODUCTS 192
14.3.2 PLATFORM-BASED PRODUCTS 192
14.3.3 KITS AND REAGENTS 192
14.3.4 OTHER CONSUMABLES 192
14.4 PROGNOSTIC 193
14.4.1 INSTRUMENT-BASED PRODUCTS 194
14.4.2 PLATFORM-BASED PRODUCTS 194
14.4.3 KITS AND REAGENTS 194
14.4.4 OTHER CONSUMABLES 194
14.5 RESEARCH 194
14.5.1 INSTRUMENT-BASED PRODUCTS 195
14.5.2 PLATFORM-BASED PRODUCTS 195
14.5.3 KITS AND REAGENTS 195
14.5.4 OTHER CONSUMABLES 195
15 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 196
15.1 OVERVIEW 197
15.2 HOSPITALS 200
15.3 DIAGNOSTIC CENTERS 200
15.4 CANCER RESEARCH CENTERS 201
15.5 ACADEMIC INSTITUTES 202
15.6 AMBULATORY SURGICAL CENTERS 203
15.7 OTHERS 204
16 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 205
16.1 OVERVIEW 206
16.2 DIRECT TENDER 209
16.3 RETAIL SALES 210
16.4 OTHERS 211
17 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 212
17.1 OVERVIEW 213
17.2 NORTH AMERICA 219
17.2.1 U.S. 233
17.2.2 CANADA 242
17.2.3 MEXICO 251
17.3 EUROPE 260
17.3.1 GERMANY 275
17.3.2 FRANCE 284
17.3.3 UNITED KINGDOM 293
17.3.4 ITALY 302
17.3.5 SPAIN 311
17.3.6 RUSSIA 320
17.3.7 NETHERLANDS 329
17.3.8 POLAND 338
17.3.9 SWITZERLAND 347
17.3.10 BELGIUM 356
17.3.11 SWEDEN 365
17.3.12 NORWAY 374
17.3.13 DENMARK 383
17.3.14 FINLAND 392
17.3.15 TURKEY 401
17.3.16 REST OF EUROPE 410
17.4 ASIA-PACIFIC 411
17.4.1 CHINA 424
17.4.2 JAPAN 432
17.4.3 INDIA 440
17.4.4 SOUTH KOREA 448
17.4.5 AUSTRALIA 456
17.4.6 TAIWAN 464
17.4.7 NEW ZEALAND 472
17.4.8 INDONESIA 480
17.4.9 THAILAND 488
17.4.10 PHILIPPINES 496
17.4.11 MALAYSIA 504
17.4.12 VIETNAM 512
17.4.13 SINGAPORE 520
17.4.14 REST OF ASIA-PACIFIC 528
17.5 SOUTH AMERICA 529
17.5.1 BRAZIL 542
17.5.2 ARGENTINA 550
17.5.3 REST OF SOUTH AMERICA 558
17.6 MIDDLE EAST AND AFRICA 559
17.6.1 SOUTH AFRICA 574
17.6.2 SAUDI ARABIA 583
17.6.3 BAHRAIN 592
17.6.4 UAE 601
17.6.5 EGYPT 610
17.6.6 ISRAEL 619
17.6.7 KUWAIT 628
17.6.8 OMAN 637
17.6.9 QATAR 646
17.6.10 REST OF MIDDLE EAST AND AFRICA 655
18 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 656
18.1 COMPANY SHARE ANALYSIS: GLOBAL 656
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 657
18.3 COMPANY SHARE ANALYSIS: EUROPE 658
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 659
19 SWOT ANALYSIS 660
20 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 661
20.1 CANON MEDICAL SYSTEMS CORPORATION 661
20.1.1 COMPANY SNAPSHOT 661
20.1.2 REVENUE ANALYSIS 661
20.1.3 COMPANY SHARE ANALYSIS 662
20.1.4 PRODUCT PORTFOLIO 662
20.1.5 RECENT DEVELOPMENT 662
20.2 KONINKLIJKE PHILIPS N.V. 663
20.2.1 COMPANY SNAPSHOT 663
20.2.2 REVENUE ANALYSIS 663
20.2.3 COMPANY SHARE ANALYSIS 664
20.2.4 PRODUCT PORTFOLIO 664
20.2.5 RECENT DEVELOPMENTS 664
20.3 SIEMENS HEALTHCARE GMBH 666
20.3.1 COMPANY SNAPSHOT 666
20.3.2 REVENUE ANALYSIS 666
20.3.3 COMPANY SHARE ANALYSIS 667
20.3.4 PRODUCT PORTFOLIO 667
20.3.5 RECENT DEVELOPMENT 668
20.4 GRAIL 669
20.4.1 COMPANY PROFILE 669
20.4.2 COMPANY SHARE ANALYSIS 669
20.4.3 PRODUCT PORTFOLIO 670
20.4.4 RECENT DEVELOPMENT 670
20.5 MYRIAD GENETICS, INC. 671
20.5.1 COMPANY SNAPSHOT 671
20.5.2 REVENUE ANALYSIS 671
20.5.3 COMPANY SHARE ANALYSIS 672
20.5.4 PRODUCT PORTFOLIO 672
20.5.5 RECENT DEVELOPMENT 672

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.